Image Description (Inner Label A)
Dihydroergotamine Mesylate Spray
Product Images NDC 73352-096
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Dihydroergotamine Mesylate (NDC 73352-096). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Trifluent Pharma, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Image Description (Outer Label A)
This is a description for a medication package containing Dihydroergotamine Mesylate Nasal Spray. This prescription is for nasal use only and should not be injected. The package includes 8 nasal spray bottles and administration instructions. It is important to discard the sprayer with an open vial after treatment completion or within 8 hours. The package insert contains further information and administration instructions. The product should be stored below 25°C (77°F) and should not be refrigerated or frozen.*
Image Description (Dihydroergotamine Mesylate Nasal Spray Figure 1a)
Estimated Probability of a Patient Responding During the Four Hours Following a Single 2 mg Dose of Dihydroergotamine Mesylate Nasal Spray as a function of the time elapsed since initiation of Studies 1 and 2. The graph shows the response rate over time in hours for patients who received the nasal spray compared to those who received a placebo.*
Image Description (Dihydroergotamine Mesylate Nasal Spray Figure 2a)
This is information regarding the estimated probability of a patient responding to dihydroergotamine mesylate nasal spray within the first four hours following dosing in Studies 3 and 4. The chart shows the probability of response for the nasal spray compared to a placebo over different time intervals. The study involved a total of 97 patients using the nasal spray and 100 patients using the placebo.*
Image Description (Dihydroergotamine Mesylate Nasal Spray Figure 3a)
This text provides a visual representation of the estimated probability of patients using additional treatments for migraine over a 24-hour period following the administration of dihydroergotamine mesylate nasal spray (2 mg) or a placebo. The graph shows the likelihood of additional treatment usage at different time points after the first spray, with data for dihydroergotamine mesylate nasal spray (N=308) compared to the placebo group (N=300).*
Image Description (Dihydroergotamine Mesylate Nasal Spray Structure A)
This text provides relevant information about the chemical composition of Dihydroergotamine mesylate, which is a medication used for treating migraines. The molecular formula (C33H37N505.CH405S) and molecular weight (679.80) are specified.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
